Pacira BioSciences, Inc. (PCRX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Pacira BioSciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 24.70 at 3:45 pm ET, low 24.44 at 9:45 am ET.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
the bull case· 1
12
disclosed supplier and customer ties in SEC filings
sec filingsedgarthe bear case· 4
31.00%
of revenue from the largest disclosed customer, McKesson Drug Company
10-Kfiled Feb 26 '267 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realized3
of the funds on file reporting a position in PCRX
n-portas of Jun 30 '2610 of 25
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 4 companies Pacira BioSciences, Inc. moves with most closely, none share its SEC classification.
Measured against 266 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
250 managers report a position worth $1.1B between them, and 30 of them hold 80% of it.
tall tick = annual report · 1 on record
PCRX (Pacira BioSciences, Inc.) has 7 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.